159 related articles for article (PubMed ID: 28326325)
1. A Potential of sFasL in Preventing Gland Injury in Sjogren's Syndrome.
Luo J; Wang Y; Yu B; Qian H; He Y; Shi G
Biomed Res Int; 2017; 2017():5981432. PubMed ID: 28326325
[TBL] [Abstract][Full Text] [Related]
2. Detection of the soluble form of Fas ligand (sFasL) and sFas in the saliva from patients with Sjögren's syndrome.
Nakamura H; Kawakami A; Izumi M; Nakashima T; Takagi Y; Ida H; Nakamura T; Nakamura T; Eguchi K
Clin Exp Rheumatol; 2005; 23(6):915. PubMed ID: 16396719
[No Abstract] [Full Text] [Related]
3. [Effect of nourishing Yin, strengthening Qi and activating blood decoction on Fas/FasL in salivary glands of NOD mice with Sjogren's syndrome and their mRNA expression].
Wu GL; Li TY; Lu WW; Yu GY; Fan YS
Zhongguo Zhong Yao Za Zhi; 2013 Dec; 38(23):4148-51. PubMed ID: 24791507
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B].
Jun EJ; Han JY; Sun HS
Korean J Hepatol; 2006 Dec; 12(4):507-14. PubMed ID: 17237628
[TBL] [Abstract][Full Text] [Related]
5. Induction of salivary gland epithelial cell injury in Sjogren's syndrome: in vitro assessment of T cell-derived cytokines and Fas protein expression.
Abu-Helu RF; Dimitriou ID; Kapsogeorgou EK; Moutsopoulos HM; Manoussakis MN
J Autoimmun; 2001 Sep; 17(2):141-53. PubMed ID: 11591123
[TBL] [Abstract][Full Text] [Related]
6. Glandular and extraglandular expression of the Fas-Fas ligand and apoptosis in patients with Sjögren's syndrome.
Matsumura R; Umemiya K; Kagami M; Tomioka H; Tanabe E; Sugiyama T; Sueishi M; Nakajima A; Azuma M; Okumura K; Sumida T
Clin Exp Rheumatol; 1998; 16(5):561-8. PubMed ID: 9779303
[TBL] [Abstract][Full Text] [Related]
7. [Apoptosis and related gene expression in lacrimal gland of cases with Sjögren's syndrome].
Wu J; Fei P; Gong Y; Zhao J; Dong J; Tang F
Zhonghua Yan Ke Za Zhi; 2000 Jul; 36(4):255-8, 14. PubMed ID: 11853607
[TBL] [Abstract][Full Text] [Related]
8. [Change in serum levels of soluble Fas and soluble FasL in patients with multiple organ dysfunction syndrome].
Fu Y; Xiao QM; Wang T; Chen XH; Ai YH
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Nov; 18(11):691-4. PubMed ID: 17092425
[TBL] [Abstract][Full Text] [Related]
9. Lack of Fas and Fas-L mutations in patients with lymphoproliferative disorders associated with Sjögren's syndrome and type II mixed cryoglobulinemia.
Bertolo F; De Vita S; Dolcetti R; Carbone A; Ferraccioli GF; Bartoli E; Boiocchi M
Clin Exp Rheumatol; 1999; 17(3):339-42. PubMed ID: 10410268
[TBL] [Abstract][Full Text] [Related]
10. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
11. FAS -670A>G promoter polymorphism is associated with soluble Fas levels in primary Sjögren's syndrome.
Treviño-Talavera BA; Palafox-Sánchez CA; Muñoz-Valle JF; Orozco-Barocio G; Navarro-Hernández RE; Vázquez-Del Mercado M; García de la Torre I; Oregon-Romero E
Genet Mol Res; 2014 Jul; 13(3):4831-8. PubMed ID: 25062418
[TBL] [Abstract][Full Text] [Related]
12. Fas and Fas ligand gene polymorphisms in primary Sjögren's syndrome.
Bolstad AI; Wargelius A; Nakken B; Haga HJ; Jonsson R
J Rheumatol; 2000 Oct; 27(10):2397-405. PubMed ID: 11036836
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of interleukin-7 in labial salivary glands of patients with primary Sjögren's syndrome correlates with increased inflammation.
Bikker A; van Woerkom JM; Kruize AA; Wenting-van Wijk M; de Jager W; Bijlsma JW; Lafeber FP; van Roon JA
Arthritis Rheum; 2010 Apr; 62(4):969-77. PubMed ID: 20131250
[TBL] [Abstract][Full Text] [Related]
14. Fas ligand-mediated exocrinopathy resembling Sjögren's syndrome in mice transgenic for IL-10.
Saito I; Haruta K; Shimuta M; Inoue H; Sakurai H; Yamada K; Ishimaru N; Higashiyama H; Sumida T; Ishida H; Suda T; Noda T; Hayashi Y; Tsubota K
J Immunol; 1999 Mar; 162(5):2488-94. PubMed ID: 10072487
[TBL] [Abstract][Full Text] [Related]
15. Unsolved mystery of Fas: mononuclear cells may have trouble dying in patients with Sjögren's syndrome.
Lindrova I; Kolackova M; Svadlakova T; Vankova R; Chmelarova M; Rosecka M; Jozifkova E; Sembera M; Krejsek J; Slezak R
BMC Immunol; 2023 Jun; 24(1):12. PubMed ID: 37353767
[TBL] [Abstract][Full Text] [Related]
16. Soluble Fas and soluble Fas L levels in patients with acute pancreatitis.
Endo S; Inoue Y; Fujino Y; Yamada Y; Sato N; Wakabayashi G; Sakamoto T; Ishikura H; Tanaka T; Inada K; Sato S
Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):179-86. PubMed ID: 11913710
[TBL] [Abstract][Full Text] [Related]
17. Inappropriate apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-scid mice.
Kong L; Robinson CP; Peck AB; Vela-Roch N; Sakata KM; Dang H; Talal N; Humphreys-Beher MG
Clin Exp Rheumatol; 1998; 16(6):675-81. PubMed ID: 9844759
[TBL] [Abstract][Full Text] [Related]
18. The sFas/sFasL ratio as a novel marker of inflammation in children with chronic kidney disease.
Musiał K; Zwolińska D
Clin Chim Acta; 2012 Dec; 414():7-11. PubMed ID: 22898262
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of Fas-ligand mRNA in Sjögren's syndrome patients with enlarged exocrine glands.
Tsuzaka K; Matsumoto Y; Sasaki Y; Abe T; Tsubota K; Takeuchi T
Autoimmunity; 2007 Nov; 40(7):497-502. PubMed ID: 17966039
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum soluble Fas ligand is a promising marker of testicular toxicity induced by epirubicin in rats.
Geng J; Fan J; Jiang HW; Fang ZJ; Wang X; Sun JL; Ding Q; Chen G
Toxicol Lett; 2009 Apr; 186(2):96-103. PubMed ID: 19429229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
